secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adaptive Biotechnologies Corp (ADPT)
CIK:        0001478320
Form:       8-K
Filed at:   2022-05-04T23:59:59+00:00
Accession:  0001564590-22-017852
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adaptive Biotechnologies Q1 revenue $38.6M (+0.5% YoY); net loss widens to $62.8M
--------------------------------------------------------------------------------

- clonoSEQ test volume grew 45% YoY and 12% QoQ; MRD regulatory milestone revenue of $3.0M from partner drug approval.
- T-Detect Lyme sensitivity 54% vs SOC 30% at 99% specificity; launch planned for 2022 Lyme season.
- Entered T-MAP collaboration with Janssen for RSV vaccine program; appointed Tycho Peterson as CFO.
- Revenue guidance for FY2022 reaffirmed at $185-195M; cash and securities $500.7M as of March 31.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1478320/000156459022017852/0001564590-22-017852-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1478320/000156459022017852/adpt-8k_20220504.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-017852

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer